Physician profile
Dane A Shoemaker
NPI 1568713675
$9,563.91
in general payments reported to CMS, 2019-2025
29 companies · $2,556 in 2025
The $2,556 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $1,791 · 2023: $2,496 · 2024: $2,282 · 2025: $2,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,245 · Education: $89.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,245.04 |
| Education | $89.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,290.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,370.76 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,246.03 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $947.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.56 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $460.88 | 2024-2025 | Omvoh |
| Celgene Corporation | $357.40 | 2021-2023 | Zeposia |
| Pfizer INC. | $315.90 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $291.33 | 2021-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $288.32 | 2022-2024 | Dificid |
| Aimmune Therapeutics, INC. | $188.13 | 2024-2025 | Zenpep |
| Genzyme Corporation | $147.62 | 2023 | |
| Madrigal Pharmaceuticals | $137.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $129.81 | 2022-2023 | |
| Fresenius Kabi USA, LLC | $119.19 | 2023-2024 | Idacio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $115.81 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $99.97 | 2022-2025 | Sutab |
| Mirum Pharmaceuticals, INC. | $92.68 | 2024 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $80.07 | 2024 | Bylvay, Iqirvo |
| Ardelyx, INC. | $77.36 | 2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $64.55 | 2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $46.60 | 2023 | Imfinzi |
| Novo Nordisk INC | $42.23 | 2025 | Wegovy |
| Qol Medical, LLC | $39.83 | 2024 | Sucraid |
| Celltrion USA INC. | $39.05 | 2024-2025 | Vegzelma |
| Biocon Biologics INC | $31.13 | 2025 | Hulio |
| Phathom Pharmaceuticals, INC. | $27.46 | 2024 | Voquezna |
| Digestive Care, INC. | $16.21 | 2023 | Pertzye |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.